Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Loaëc N[au]:

Search results

Items: 30

1.

Sneaking Out for Happy Hour: Yeast-Based Approaches to Explore and Modulate Immune Response and Immune Evasion.

Angrand G, Quillévéré A, Loaëc N, Daskalogianni C, Granzhan A, Teulade-Fichou MP, Fahraeus R, Prado Martins R, Blondel M.

Genes (Basel). 2019 Aug 31;10(9). pii: E667. doi: 10.3390/genes10090667. Review.

2.

Novel cationic bis(acylhydrazones) as modulators of Epstein-Barr virus immune evasion acting through disruption of interaction between nucleolin and G-quadruplexes of EBNA1 mRNA.

Reznichenko O, Quillévéré A, Martins RP, Loaëc N, Kang H, Lista MJ, Beauvineau C, González-García J, Guillot R, Voisset C, Daskalogianni C, Fåhraeus R, Teulade-Fichou MP, Blondel M, Granzhan A.

Eur J Med Chem. 2019 Sep 15;178:13-29. doi: 10.1016/j.ejmech.2019.05.042. Epub 2019 May 23.

PMID:
31173968
3.

Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a.

Marechal D, Brault V, Leon A, Martin D, Lopes Pereira P, Loaëc N, Birling MC, Friocourt G, Blondel M, Herault Y.

Hum Mol Genet. 2019 May 1;28(9):1561-1577. doi: 10.1093/hmg/ddy447.

PMID:
30649339
4.

Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.

Nguyen TL, Duchon A, Manousopoulou A, Loaëc N, Villiers B, Pani G, Karatas M, Mechling AE, Harsan LA, Limanton E, Bazureau JP, Carreaux F, Garbis SD, Meijer L, Herault Y.

Dis Model Mech. 2018 Sep 27;11(9). pii: dmm035634. doi: 10.1242/dmm.035634.

5.

Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.

Walter A, Chaikuad A, Helmer R, Loaëc N, Preu L, Ott I, Knapp S, Meijer L, Kunick C.

PLoS One. 2018 May 3;13(5):e0196761. doi: 10.1371/journal.pone.0196761. eCollection 2018.

6.

A new mouse model of ARX dup24 recapitulates the patients' behavioral and fine motor alterations.

Dubos A, Meziane H, Iacono G, Curie A, Riet F, Martin C, Loaëc N, Birling MC, Selloum M, Normand E, Pavlovic G, Sorg T, Stunnenberg HG, Chelly J, Humeau Y, Friocourt G, Hérault Y.

Hum Mol Genet. 2018 Jun 15;27(12):2138-2153. doi: 10.1093/hmg/ddy122.

7.

Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design.

Meine R, Becker W, Falke H, Preu L, Loaëc N, Meijer L, Kunick C.

Molecules. 2018 Jan 24;23(2). pii: E64. doi: 10.3390/molecules23020064.

8.

Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases.

Loaëc N, Attanasio E, Villiers B, Durieu E, Tahtouh T, Cam M, Davis RA, Alencar A, Roué M, Bourguet-Kondracki ML, Proksch P, Limanton E, Guiheneuf S, Carreaux F, Bazureau JP, Klautau M, Meijer L.

Mar Drugs. 2017 Oct 17;15(10). pii: E316. doi: 10.3390/md15100316. Review.

9.

Identification of CLK1 Inhibitors by a Fragment-linking Based Virtual Screening.

Walter A, Chaikuad A, Loaëc N, Preu L, Knapp S, Meijer L, Kunick C, Koch O.

Mol Inform. 2017 Apr;36(4). doi: 10.1002/minf.201600123. Epub 2016 Dec 21.

PMID:
28000414
10.

Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor.

Bendjeddou LZ, Loaëc N, Villiers B, Prina E, Späth GF, Galons H, Meijer L, Oumata N.

Eur J Med Chem. 2017 Jan 5;125:696-709. doi: 10.1016/j.ejmech.2016.09.064. Epub 2016 Sep 22.

PMID:
27721154
11.

Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives.

Zeinyeh W, Esvan YJ, Nauton L, Loaëc N, Meijer L, Théry V, Anizon F, Giraud F, Moreau P.

Bioorg Med Chem Lett. 2016 Sep 1;26(17):4327-9. doi: 10.1016/j.bmcl.2016.07.032. Epub 2016 Jul 16.

PMID:
27469128
12.

5-Substituted 3-chlorokenpaullone derivatives are potent inhibitors of Trypanosoma brucei bloodstream forms.

Orban OC, Korn RS, Benítez D, Medeiros A, Preu L, Loaëc N, Meijer L, Koch O, Comini MA, Kunick C.

Bioorg Med Chem. 2016 Aug 15;24(16):3790-800. doi: 10.1016/j.bmc.2016.06.023. Epub 2016 Jun 13.

PMID:
27349574
13.

Synthesis of Bioactive 2-(Arylamino)thiazolo[5,4-f]-quinazolin-9-ones via the Hügershoff Reaction or Cu- Catalyzed Intramolecular C-S Bond Formation.

Hédou D, Dubouilh-Benard C, Loaëc N, Meijer L, Fruit C, Besson T.

Molecules. 2016 Jun 18;21(6). pii: E794. doi: 10.3390/molecules21060794.

14.

Synthesis of Thiazolo[5,4-f]quinazolin-9(8H)-ones as Multi-Target Directed Ligands of Ser/Thr Kinases.

Hédou D, Godeau J, Loaëc N, Meijer L, Fruit C, Besson T.

Molecules. 2016 Apr 30;21(5). pii: E578. doi: 10.3390/molecules21050578.

15.

Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure.

Esvan YJ, Zeinyeh W, Boibessot T, Nauton L, Théry V, Knapp S, Chaikuad A, Loaëc N, Meijer L, Anizon F, Giraud F, Moreau P.

Eur J Med Chem. 2016 Aug 8;118:170-7. doi: 10.1016/j.ejmech.2016.04.004. Epub 2016 Apr 5.

PMID:
27128181
16.

Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Meijer L, Nelson DJ, Riazanski V, Gabdoulkhakova AG, Hery-Arnaud G, Le Berre R, Loaëc N, Oumata N, Galons H, Nowak E, Gueganton L, Dorothée G, Prochazkova M, Hall B, Kulkarni AB, Gray RD, Rossi AG, Witko-Sarsat V, Norez C, Becq F, Ravel D, Mottier D, Rault G.

J Innate Immun. 2016;8(4):330-49. doi: 10.1159/000444256. Epub 2016 Mar 18. Review.

17.

TRPC6 channel translocation into phagosomal membrane augments phagosomal function.

Riazanski V, Gabdoulkhakova AG, Boynton LS, Eguchi RR, Deriy LV, Hogarth DK, Loaëc N, Oumata N, Galons H, Brown ME, Shevchenko P, Gallan AJ, Yoo SG, Naren AP, Villereal ML, Beacham DW, Bindokas VP, Birnbaumer L, Meijer L, Nelson DJ.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6486-95. doi: 10.1073/pnas.1518966112. Epub 2015 Nov 10.

18.

Novel Adociaquinone Derivatives from the Indonesian Sponge Xestospongia sp.

He F, Mai LH, Longeon A, Copp BR, Loaëc N, Bescond A, Meijer L, Bourguet-Kondracki ML.

Mar Drugs. 2015 Apr 28;13(5):2617-28. doi: 10.3390/md13052617.

19.

10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.

Falke H, Chaikuad A, Becker A, Loaëc N, Lozach O, Abu Jhaisha S, Becker W, Jones PG, Preu L, Baumann K, Knapp S, Meijer L, Kunick C.

J Med Chem. 2015 Apr 9;58(7):3131-43. doi: 10.1021/jm501994d. Epub 2015 Mar 23.

20.

Synthesis and molecular modelling studies of 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors.

Loidreau Y, Deau E, Marchand P, Nourrisson MR, Logé C, Coadou G, Loaëc N, Meijer L, Besson T.

Eur J Med Chem. 2015 Mar 6;92:124-34. doi: 10.1016/j.ejmech.2014.12.038. Epub 2014 Dec 23.

PMID:
25549552
21.

Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I.

Foucourt A, Hédou D, Dubouilh-Benard C, Désiré L, Casagrande AS, Leblond B, Loäec N, Meijer L, Besson T.

Molecules. 2014 Sep 29;19(10):15546-71. doi: 10.3390/molecules191015546.

22.

9- and 11-Substituted 4-azapaullones are potent and selective inhibitors of African trypanosoma.

Maiwald F, Benítez D, Charquero D, Dar MA, Erdmann H, Preu L, Koch O, Hölscher C, Loaëc N, Meijer L, Comini MA, Kunick C.

Eur J Med Chem. 2014 Aug 18;83:274-83. doi: 10.1016/j.ejmech.2014.06.020. Epub 2014 Jun 11.

PMID:
24973661
23.

Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.

Jarry M, Lecointre C, Malleval C, Desrues L, Schouft MT, Lejoncour V, Liger F, Lyvinec G, Joseph B, Loaëc N, Meijer L, Honnorat J, Gandolfo P, Castel H.

Neuro Oncol. 2014 Nov;16(11):1484-98. doi: 10.1093/neuonc/nou102. Epub 2014 Jun 2.

24.

Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors.

Beniddir MA, Le Borgne E, Iorga BI, Loaëc N, Lozach O, Meijer L, Awang K, Litaudon M.

J Nat Prod. 2014 May 23;77(5):1117-22. doi: 10.1021/np400856h. Epub 2014 May 5.

PMID:
24798019
25.

CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.

Delehouzé C, Godl K, Loaëc N, Bruyère C, Desban N, Oumata N, Galons H, Roumeliotis TI, Giannopoulou EG, Grenet J, Twitchell D, Lahti J, Mouchet N, Galibert MD, Garbis SD, Meijer L.

Oncogene. 2014 Dec 11;33(50):5675-87. doi: 10.1038/onc.2013.513. Epub 2013 Dec 9.

26.

Synthesis of novel 7-substituted pyrido[2',3':4,5]furo[3,2-d]pyrimidin-4-amines and their N-aryl analogues and evaluation of their inhibitory activity against Ser/Thr kinases.

Deau E, Loidreau Y, Marchand P, Nourrisson MR, Loaëc N, Meijer L, Levacher V, Besson T.

Bioorg Med Chem Lett. 2013 Dec 15;23(24):6784-8. doi: 10.1016/j.bmcl.2013.10.019. Epub 2013 Oct 17.

PMID:
24176400
27.

Synthesis, resolution, and biological evaluation of atropisomeric (aR)- and (aS)-16-methyllamellarins N: unique effects of the axial chirality on the selectivity of protein kinases inhibition.

Yoshida K, Itoyama R, Yamahira M, Tanaka J, Loaëc N, Lozach O, Durieu E, Fukuda T, Ishibashi F, Meijer L, Iwao M.

J Med Chem. 2013 Sep 26;56(18):7289-301. doi: 10.1021/jm400719y. Epub 2013 Sep 13.

PMID:
23981088
28.

Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases.

Loidreau Y, Marchand P, Dubouilh-Benard C, Nourrisson MR, Duflos M, Loaëc N, Meijer L, Besson T.

Eur J Med Chem. 2013 Jan;59:283-95. doi: 10.1016/j.ejmech.2012.11.030. Epub 2012 Nov 24.

PMID:
23237976
29.

Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors.

Loidreau Y, Marchand P, Dubouilh-Benard C, Nourrisson MR, Duflos M, Lozach O, Loaëc N, Meijer L, Besson T.

Eur J Med Chem. 2012 Dec;58:171-83. doi: 10.1016/j.ejmech.2012.10.006. Epub 2012 Oct 16.

PMID:
23124214
30.

CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells.

Bettayeb K, Baunbæk D, Delehouze C, Loaëc N, Hole AJ, Baumli S, Endicott JA, Douc-Rasy S, Bénard J, Oumata N, Galons H, Meijer L.

Genes Cancer. 2010 Apr;1(4):369-80. doi: 10.1177/1947601910369817.

Supplemental Content

Support Center